John Reneau

Academic / Other · 2 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cel Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma	Phase 1	2022-05-06
Completed	Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymp Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Phase 2	2018-03-16